Integra Lifesciences Holdings Corp (IART) Stock Price & Analysis
Integra Lifesciences Holdings Corp (IART) rose 1.70% to USD 16.72 as of September 8, 2026 at 05:42 UTC, according to Nexqual real-time market data.
IART last closed at USD 16.44; the session ranged USD 16.25–16.78 on volume of 674,913 shares. Market capitalization is $1.30B, with a 52-week range of USD 8.7–20.49 (NMS). Source: Nexqual, September 8, 2026 at 05:42 UTC.
Key Statistics (as of September 8, 2026 at 05:42 UTC)
| Price | USD 16.72 |
|---|---|
| Change | ▲ 1.70% (up) |
| Previous Close | USD 16.44 |
| Open | USD 16.32 |
| Day Range | USD 16.25 – 16.78 |
| 52-Week Range | USD 8.7 – 20.49 |
| Volume | 674,913 shares |
| Market Cap | $1.30B |
| Exchange | NMS |
Technical Analysis (IART)
Nexqual's technical model rates IART "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:42 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.78 (neutral) |
| vs SMA50 | Below (USD 17.81) |
| MACD | -0.3 (negative) |
Analyst Ratings (IART)
Wall Street analysts rate IART "Hold" based on 9 analysts, with a mean price target of USD 19.56 (range USD 14–27), per Nexqual as of September 8, 2026 at 05:42 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 19.56 |
| High Target | USD 27 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 3 / 7 / 2 |
Earnings (IART)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.56 |
| Revenue Estimate | $416.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.56 vs est 0.48 ▲ beat |
| 2026-03-31 | USD 0.54 vs est 0.4 ▲ beat |
| 2025-12-31 | USD 0.83 vs est 0.8 ▲ beat |
| 2025-09-30 | USD 0.54 vs est 0.43 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Financials & Fundamentals (IART)
| Total Revenue | $1.65B |
|---|---|
| Revenue Growth (YoY) | +0.80% |
| Gross Margin | +56.87% |
| Operating Margin | +9.62% |
| Profit Margin | -0.44% |
| ROE | -0.70% |
| Debt / Equity | 196.49 |
| Current Ratio | 3.6 |
| Total Cash | $274.08M |
| Total Debt | $2.05B |
| Free Cash Flow | $94.40M |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Financial Health Score (IART)
Nexqual rates Integra Lifesciences Holdings Corp's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:42 UTC.
| Growth | Mixed — Revenue +1.5% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 10% |
| Balance Sheet | Weak — $274M cash vs $2.05B debt |
| Cash Flow | Solid — FCF $94M, 6% margin |
| Efficiency | Critical — ROE -1%, ROA 2.8% |
Ownership (IART)
| Insider Ownership | +14.30% |
|---|---|
| Institutional Ownership | +98.39% |
| Shares Outstanding | 77.77M |
| Float | 58.68M |
| Short % of Float | +11.95% |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
Leadership (IART)
Integra Lifesciences Holdings Corp is led by Stuart M. Essig (age 63), CEO, President & Chairman, per Nexqual as of September 8, 2026 at 05:42 UTC.
| CEO, President & Chairman | Stuart M. Essig (age 63) |
|---|---|
| Executive VP & CFO | Lea Daniels Knight (age 53) |
| Executive Vice President of Tissue Reconstruction and Distributed Technologies | Robert T. Davis (age 66) |
| Executive VP & President of International Business | Harvinder Pal Singh (age 59) |
| Corporate VP & Chief Technology Officer | Teshtar Elavia |
Major Backers & Investors (IART)
Notable institutional backers of Integra Lifesciences Holdings Corp include Rubric Capital Management LP, Invesco, Morgan Stanley, according to Nexqual as of September 8, 2026 at 05:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 9.97% |
| Invesco | 4.82% |
| Morgan Stanley | 4.62% |
| Fuller & Thaler Asset Management Inc. | 4.42% |
| Paradigm Capital Management | 4.42% |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.36% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 3.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 21.27% |
| Vanguard Group | 15.49% |
| State Street | 3.79% |
Source: Nexqual, September 8, 2026 at 05:42 UTC.
From Integra Lifesciences Holdings Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
- It operates through Codman Specialty Surgical and Tissue Technologies segments.
- The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
- It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICUI | ICU Medical, Inc. | USD 167.58 | ▼ 1.34% |
| CNMD | CONMED Corporation | USD 49.32 | ▼ 0.22% |
| HAE | Haemonetics Corporation | USD 102.92 | ▲ 0% |
| MMSI | Merit Medical Systems, Inc. | USD 89.6 | ▼ 0.59% |
| OFIX | Orthofix Medical Inc. | USD 9.29 | ▼ 0.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:42 UTC. This page is informational and not investment advice.